Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
When index levels rise, adjust allocations gradually and monitor sectors leading the move. This intro provides simple steps to respond without overreacting.
19,220 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
ASML, Europe’s largest semiconductor equipment maker, is poised to report second-quarter results as AI-driven demand ...
Jim Cramer's ongoing Nvidia purchases rest on one core belief: the CUDA software moat that underpins Nvidia's AI lead...
Investors are using margin loans to amplify gains, but rising leverage could trigger sharp moves. The latest margin d...
Visa and Mastercard operate the core rails of digital payments. Both offer durable moats, steady cash flow, and limit...
High-income retirees who wait until age 70 to claim Social Security may face a hidden tax bill, Medicare surcharges, ...
A Massachusetts man fell for a phony online romance that morphed into a fake crypto investment. He ended up losing hu...
AI is lifting chip demand to new heights. This guide explains the drivers, what the forecast means for investors, and...
Morgan Stanley's latest bottom up view argues that AI infrastructure demand will outpace supply, turning the Nebius s...
A new forecast from the most powerful claude model signals a substantial Solana rally by year-end 2026, backed by ris...
Ethereum climbs past $1,900 as Arthur Hayes makes a fresh ETH buy, renewing debate about his trading approach and the...
When big builders cut prices to move inventory, investors win—if they know how to structure deals. This guide breaks ...